Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

Future Oncology

Volumn 1, Issue 4, 2005, Pages 461-466

  Riedel, Richard F ^a   Febbo, Phillip G ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

epidermal growth factor receptor; gefitinib; mutation; non small cell lung cancer; resistance; sensitivity; tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MUTATION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33744491285     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.4.461     Document Type: Article

References (17)

1. Jemal A, Murray T, Ward E et al.: Cancer Statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005
2. Schiller JH, Harrington DH, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002
3. Dougall WC, Qian X, Greene MI: Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J. Cell. Biochem. 53(1), 61-73 (1993
4. Fukuoka M, Yano S, Giaccone G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial). J. Clin. Oncol. 21(12), 2237-2246 (2003
5. Kris MG, Natale RB, Herbst RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 290(16), 2149-2158 (2003
6. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial -INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004
7. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial -INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004
8. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004
9. Paez JG, Jnne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004
10. Bekaii-Saab TS: Intragenic EGFR and EGFR2 mutations in hepatobiliary tumors and potential role in predicting response to agents that target EGFR. Proceeding of the Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May 2005 (Abstract 4037
11. Lee JW, Soung YH, Kim SY et al.: Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11(8), 2879-2882 (2005
12. Pollack A: Huge genome project is proposed to fight cancer. New York Times A1, 28 March 2005.
13. Gabor Miklos GL: The human cancer genome project -one more misstep in the war on cancer. Nature Biotechnol. 23(5), 535-537 (2005
14. Kobayashi S, Boggon TJ, Dayaram T et al.: EGFR mutation and resistance of nonsmall-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005
15. Pao W, Miller VA, Politi KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), E73 (2005
16. Branford S, Rudzki Z, Walsh S et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475 (2002
17. Chen LL, Trent JC, Wu EF et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64(17), 5913-5919 (2004